AR047749A1 - CRYSTAL COMPOSITION CONTAINING ESCITALOPRAM - Google Patents

CRYSTAL COMPOSITION CONTAINING ESCITALOPRAM

Info

Publication number
AR047749A1
AR047749A1 ARP050100683A ARP050100683A AR047749A1 AR 047749 A1 AR047749 A1 AR 047749A1 AR P050100683 A ARP050100683 A AR P050100683A AR P050100683 A ARP050100683 A AR P050100683A AR 047749 A1 AR047749 A1 AR 047749A1
Authority
AR
Argentina
Prior art keywords
escitalopram
particles
composition containing
crystal composition
escitalopram oxalate
Prior art date
Application number
ARP050100683A
Other languages
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR047749A1 publication Critical patent/AR047749A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

Partículas cristalinas de oxalato de escitalopram que tienen o bien una amplia distribucion de tamano de partícula o comprenden por lo menos 0,01 % (p/p) de Z-4-(4-dimetilamino-1-(4-fluorfenil)-but-1-enilo)-3-hidroxi-metil-benzonitrilo, donde dichas partículas son apropiadas para ser usadas en compresion directa. Forma de dosificacion farmacéutica unitaria que contiene dichas partículas cristalinas de oxalato de escitalopram así como también métodos de manufactura de dichas partículas de oxalato de escitalopram. Método para la reduccion de la cantidad de hidroxilo que contiene impurezas en una solucion de citalopram o escitalopram. Método de manufactura de partículas.Crystalline particles of escitalopram oxalate that have either a wide particle size distribution or comprise at least 0.01% (w / w) of Z-4- (4-dimethylamino-1- (4-fluorphenyl) -but -1-enyl) -3-hydroxy-methyl-benzonitrile, where said particles are suitable for use in direct compression. Unitary pharmaceutical dosage form containing said crystalline particles of escitalopram oxalate as well as manufacturing methods of said escitalopram oxalate particles. Method for reducing the amount of hydroxyl containing impurities in a solution of citalopram or escitalopram. Particle manufacturing method.

ARP050100683A 2004-03-05 2005-02-24 CRYSTAL COMPOSITION CONTAINING ESCITALOPRAM AR047749A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200400382 2004-03-05

Publications (1)

Publication Number Publication Date
AR047749A1 true AR047749A1 (en) 2006-02-15

Family

ID=36607154

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100683A AR047749A1 (en) 2004-03-05 2005-02-24 CRYSTAL COMPOSITION CONTAINING ESCITALOPRAM

Country Status (9)

Country Link
KR (1) KR20060126587A (en)
CN (3) CN101492435A (en)
AR (1) AR047749A1 (en)
IL (1) IL177504A0 (en)
MY (1) MY142756A (en)
PE (1) PE20051162A1 (en)
SG (1) SG159504A1 (en)
TW (1) TW200605916A (en)
ZA (1) ZA200607382B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114763343A (en) * 2021-01-14 2022-07-19 浙江华海药业股份有限公司 Method for purifying citalopram or S-citalopram
CN113663356B (en) * 2021-08-23 2022-09-23 广西埃索凯新材料科技有限公司 Crystallization impurity removal monitoring system applied to manganese sulfate production

Also Published As

Publication number Publication date
TW200605916A (en) 2006-02-16
CN1925844A (en) 2007-03-07
ZA200607382B (en) 2008-05-28
CN101492435A (en) 2009-07-29
IL177504A0 (en) 2006-12-10
MY142756A (en) 2010-12-31
KR20060126587A (en) 2006-12-07
CN101492436A (en) 2009-07-29
SG159504A1 (en) 2010-03-30
PE20051162A1 (en) 2006-01-16

Similar Documents

Publication Publication Date Title
BRPI0508769A (en) tamper-resistant dosage form comprising an adsorbent and an adverse agent
ATE530577T1 (en) EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF APPLICATION THEREOF
EP2520311A3 (en) Method of treating hemolytic disease
ATE314062T1 (en) COMPOSITIONS FOR DELIVERING CORTISOL ANTAGONISTS
JP2005507881A5 (en)
MX2009004986A (en) Methods of treating hemolytic anemia.
WO2007143607A3 (en) Method of treating atrophic vaginitis
CL2007002018A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED ISOXAZOLINS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND FOR THE TREATMENT OF A DISEASE CAUSED BY AN INCREASE IN THE CELL PROLIFERATION.
CY1111369T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 3- (3-DIMETHYLAMINE-1-ETHYL-2-Methyl-PROPYL) -PHENOL AND PARAKETAMOL
MX2010002926A (en) Thieno-and furo-pyrimidine modulators of the histamine h4 receptor.
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
WO2010019611A3 (en) Bridged polycyclic compound based compositions for topical and oral applications
PA8501501A1 (en) EXTRUIBLE CEMENTOUS MATERIAL
WO2007087026A3 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
BR0307518A (en) Pharmaceutical Composition
AR047749A1 (en) CRYSTAL COMPOSITION CONTAINING ESCITALOPRAM
WO2006048261A3 (en) Oral solid dosage forms containing a low dose of estradiol
EA200601641A1 (en) CRYSTAL COMPOSITION CONTAINING ESCYTAL PREMAX OXALATE
BRPI0415571A (en) cleaning compositions
UY28789A1 (en) CRYSTAL COMPOSITION CONTAINING SCITALOPRAM
FR2809725B1 (en) PROPANOLAMINOTETRALINS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
PE20090479A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF AN ANTI-CONFUSION AGENT AND A BENZODIAZEPINE AGENT, INDICATED FOR THE CONTROL AND TREATMENT OF SEIZURE DISORDERS AND EPILEPTIC SYNDROMES
WO2005034972A3 (en) Use of pharmaceutical compositions containing evening primrose oil for the treatment of xerostomia
SG163512A1 (en) Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion
TH75367B (en) Mixtures for mercury distribution and manufacturing processes for these mixtures

Legal Events

Date Code Title Description
FA Abandonment or withdrawal